GlobeNewswire

Karolinska Development’s portfolio company OssDsign reports favourable outcome data on OSSDSIGN Cranial PSI

Share

STOCKHOLM, SWEDEN – November 7, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has released updated outcome data which reveals that the rate of infections leading to implant removal of OSSDSIGN Cranial PSI remained low (2.4%) after a median follow-up time of 17 months.

Reconstruction of cranial defects can be a complex surgical procedure associated with an underestimated morbidity. This post-market surveillance report describes the outcome of 670 cranioplasties using OSSDSIGN Cranial PSI, a patient-specific implant made from a calcium phosphate material reinforced with 3D-printed titanium. All data was collected as part of post-market surveillance of product performance.  

One of the most common causes of explantation of implants are early post-operative infections. In the medical literature, explantation rates due to infection with traditional implants range between 7 and 12%. The OssDsign post-market-surveillance data however shows that at a median follow up time of 17 months (range: 0-58 months) only 16 (2.4%) of the implants were explanted due to early postoperative infections.  A peer-reviewed clinical study of OSSDSIGN Cranial reported similarly low rates of infections leading to implant removal (1.9%), as has previously reported post-market surveillance data.

Histological analysis of several implants explanted ≥ 9 months following surgery revealed bony integration between the implant and the native bone, as well as new bone formation within and around the remaining calcium phosphate material. The capacity of OssDsign’s material to remodel into living bone tissue has been documented in previous peer-reviewed scientific literature as well.

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com


Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Úlfar Freyr Stefánsson appointed Chief Risk Officer of Arion Bank – Gísli S. Óttarsson leaves the Bank25.5.2020 18:50:52 CESTPress release

Úlfar Freyr Stefánsson has been appointed Chief Risk Officer of Arion Bank. Úlfar is taking over from Gísli S. Óttarsson who will be leaving the Bank after having been Chief Risk Officer and a member of the Bank’s executive committee since 2009. Gísli will step down at the end of the month but will continue to work in an advisory capacity for the Bank. Úlfar joined the Bank’s Risk Management division in 2013 after having worked at Kaupthing since 2010, where his positions included head of risk management. Úlfar was Head of Portfolio Risk at Arion Bank from 2013 to 2015, when he took over as Head of Balance Sheet Risk. Úlfar has a doctorate in mathematics from Georgia Institute of Technology and a master’s from the same institution. He also has a BSc in mathematics from the University of Iceland and is a certified securities broker. Benedikt Gíslason, CEO of Arion Bank: “I would like to thank Gísli for his excellent work and vital contribution to the Bank over the years. His successor a

PRESS RELEASE: NACON: 2019/20 ANNUAL RESULTS25.5.2020 18:34:13 CESTPress release

Press release Lesquin, 25 May 2020, 18 :00 hrs Strong growth of profitability in 2019/20: ·Current Operating Profit: 22,6 M€ (+80,3%) ·Net Résult: 15,3 M€ (+41,8%) Outlook 2020/21 : ·Sales between 140 and 150 M€ ·Current Operating Profit Rate: 18% NACON (ISIN FR0013482791) today releases its audited consolidated results for the financial year closing on 31 March 2020 as approved by its Board of directors on 25 May 2020. Consolidated in M€ IFRS03/2020 (4)03/2019 (3) Var.Sales129.4113.1+14.4%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 79.1 61.1% 48.4 37.4% 62.4 55.2% 33.4 29.5%+26.7% +45.0%Result from current operations In % of Sales Non recurrent items (including Bonus Shares)22.6 17.5% (2.0)12.5 11.1% 0.8 +80.3% Operating result In % of Sales20.6 15.9%13.4 11.8%+53.8%Financial result Including currency gain (loss)(0.6)(0.4) Earnings before tax In % of Sales20.0 15.4%13.0 11.5%+53.6%Tax(4.7)(2.2)Net result for the period In % of Sales15.3 11.8%10.8 9.5% +41.8% (1) Gross marg

PRESS RELEASE: BIGBEN: 2019/20 Annual Résults25.5.2020 18:15:16 CESTPress release

Press release Lesquin, 25 May 2020 18:00 2019/20 Annual Résults: ·Sales: 263.5 M€ (+7.3%) ·Current Operating Income: 23.7 M€ (+9.0%) ·Net Résult: 16.2 M€ (-6.3%) New « BIGBEN 2023 » plan: ·2022/23 sales: 350 M€ ·2022/23 Current Operating Income Rate: 13% BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its audited consolidated results for the financial year closing on 31 March 2020 as approved by its Board of directors on 25 May 2020. Consolidated in M€ IFRS03/202003/2019 Change.Sales263.5245.5+7.3%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 108.9 41,3% 52.5 19.9% 97.6 39.8% 44.9 18.3%+11.6% +16.8%Result from current operations In % of Sales Non recurrent items (including Bonus Shares)23.7 9.0% (2.9)21.7 8.9% 0.6 +9.0% Operating result In % of Sales20.8 7.9%22.3 9.1%-6.7%Financial result Including currency gain (loss)(1.1) 0.30.5 1.5 Earnings before tax In % of Sales19.7 7.5%22.8 9.3%-13.3%Tax(3.5)(5.4)Net result for the period In % of Sales16.2 6.2%17.3 7.1% -6.3% Of

Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate25.5.2020 17:45:00 CESTPress release

New patent granted by the CNIPA is directed at the use of lanifibranor for the treatment of several fibrotic diseases, including NASH, and expires in June 2035 The patent expands the existing patent portfolio for lanifibranor in the world’s second largest pharmaceutical market1 Daix (France), May 25, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the China National Intellectual Property Administration (CNIPA) granted a new patent directed at the use of lanifibranor for the treatment of several fibrotic diseases in China until June 2035. This new patent covers, among others, the use of the Company’s lead product candidate lanifibranor for the treatment of NASH, hepatic fibrosis, chronic renal failure and fibrotic pulmonary disorder. It thereby expands the

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER25.5.2020 16:20:00 CESTPress release

Bid procedure on 27 May 2020 Certificate: Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 27 November 2020 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 18 May 2020. Bids: Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se. Bid date: Wednesday 27 May 2020 Bid time: 0900-0930 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 4 billion Highest permitted bid volume: (corresponding nominal amount) The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in e